Critical Issues Need Answers: Providing Best Options For Myeloma (ASH 2014)
Recorded at ASH 2014
Format and Topics:
When to Treat Patients With Smoldering Myeloma
At the conclusion of the activity, participants should be able to:
Incorporate emerging data into the management algorithm for patients with high-risk smoldering multiple myeloma
Assess response and minimal residual disease to make informed treatment decisions for patients with multiple myeloma in the transplant?eligible and –ineligible settings
Choose optimal maintenance therapy for patients with multiple myeloma to extend and improve outcomes
Integrate current best practices for salvage therapy in patients with relapsed/refractory multiple myeloma to improve responses
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This activity is supported by Bristol-Myers Squibb, Celgene Corporation, Millennium Takeda, Onyx, and The Binding Site.
Jointly sponsored by the International Myeloma Foundation, Annenberg Center for Health Sciences at Eisenhower, and Clinical Care Options